Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis
Open Access
- 9 March 2020
- Vol. 10 (3), e035080
- https://doi.org/10.1136/bmjopen-2019-035080
Abstract
Introduction Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders. Methods and analysis PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration’s ‘Risk of Bias’ tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I2 model. Ethics and dissemination This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences. Trial registration number CRD42020153292.This publication has 34 references indexed in Scilit:
- Cognitive-behavioural interventions for children who have been sexually abusedEmergencias, 2012
- MinocyclineCNS Drugs, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- A Role for Non-Antimicrobial Actions of Tetracyclines in Combating Oxidative Stress in Periodontal and Metabolic Diseases: A Literature ReviewThe Open Dentistry Journal, 2008
- Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical‐scavenging activityJournal of Neurochemistry, 2005
- Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse modelExperimental Neurology, 2004
- Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's diseaseEuropean Journal of Neuroscience, 2004
- Minocycline Up-regulates Bcl-2 and Protects against Cell Death in MitochondriaOnline Journal of Public Health Informatics, 2004
- Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial ResistanceMicrobiology and Molecular Biology Reviews, 2001